<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 3</label>
 <caption>
  <p>Adverse events in the safety population</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="2"/>
    <th colspan="3">All patients (n = 49)</th>
   </tr>
   <tr>
    <th>Grade 1–2</th>
    <th>Grade 3</th>
    <th>Grade 4</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Neutropenia</td>
    <td>2 (4.1%)</td>
    <td>6 (12.2%)</td>
    <td>10 (20.4%)</td>
   </tr>
   <tr>
    <td>Fatigue</td>
    <td>17 (34.7%)</td>
    <td>2 (4.1%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Pyrexia</td>
    <td>18 (36.7%)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Thrombocytopenia</td>
    <td>11 (22.4%)</td>
    <td>3 (6.1%)</td>
    <td>4 (8.2%)</td>
   </tr>
   <tr>
    <td>Nausea</td>
    <td>15 (30.6%)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Diarrhea</td>
    <td>9 (18.4%)</td>
    <td>2 (4.1%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Asthenia</td>
    <td>8 (16.3%)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Anemia</td>
    <td>6 (12.2%)</td>
    <td>1 (2.0%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Febrile neutropenia</td>
    <td>0</td>
    <td>6 (12.2%)</td>
    <td>1 (2.0%)</td>
   </tr>
   <tr>
    <td>Constipation</td>
    <td>7 (14.3%)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Decreased appetite</td>
    <td>7 (14.3%)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Dyspnea</td>
    <td>6 (12.2%)</td>
    <td>1 (2.0%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Odema peripheral</td>
    <td>6 (12.2%)</td>
    <td>1 (2.0%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Increased ALT*</td>
    <td>4 (8.2%)</td>
    <td>2 (4.1%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Increased AST*</td>
    <td>5 (10.2%)</td>
    <td>1 (2.0%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Hypokalemia</td>
    <td>5 (10.2%)</td>
    <td>1 (2.0%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Hyperglycemia</td>
    <td>4 (8.2%)</td>
    <td>1 (2.0%)</td>
    <td>1 (2.0%)</td>
   </tr>
   <tr>
    <td>Chills</td>
    <td>6 (12.2%)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Muscular weakness</td>
    <td>5 (10.2%)</td>
    <td>0</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Leukopenia</td>
    <td>0</td>
    <td>4 (8.2%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Decreased platelet count</td>
    <td>2 (4.1%)</td>
    <td>2 (4.1%)</td>
    <td>0</td>
   </tr>
   <tr>
    <td>Pneumonia</td>
    <td>1 (2.0%)</td>
    <td>2 (4.1%)</td>
    <td>0</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>Table contains all adverse events of any grade occurring in &gt;10% of patients in the study population, and any grade 3 or worse event occurring in 2 or more patients</p>
  <p>*ALT, alanine aminotransferase; AST, aspartate aminotransferase</p>
 </table-wrap-foot>
</table-wrap>
